Related Experiment Video
Updated: Oct 20, 2025

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
Published on: February 17, 2019
Enzymatically Forming Intranuclear Peptide Assemblies for Selectively Killing Human Induced Pluripotent Stem Cells
Shuang Liu1,2, Qiuxin Zhang1, Adrianna N Shy1
1Department of Chemistry, Brandeis University, 415 South Street, Waltham, Massachusetts 02454, United States.
Abstract:
Tumorigenic risk of undifferentiated human induced pluripotent stem cells (iPSCs), being a major obstacle for clinical application of iPSCs, requires novel approaches for selectively eliminating undifferentiated iPSCs. Here, we show that an l-phosphopentapeptide, upon the dephosphorylation catalyzed by alkaline phosphatase (ALP) overexpressed by iPSCs, rapidly forms intranuclear peptide assemblies made of α-helices to selectively kill iPSCs. The phosphopentapeptide, consisting of four l-leucine residues and a C-terminal l-phosphotyrosine, self-assembles to form micelles/nanoparticles, which transform into peptide nanofibers/nanoribbons after enzymatic dephosphorylation removes the phosphate group from the l-phosphotyrosine. The concentration of ALP and incubation time dictates the morphology of the peptide assemblies. Circular dichroism and FTIR indicate that the l-pentapeptide in the assemblies contains a mixture of an α-helix and aggregated strands. Incubating the l-phosphopentapeptide with human iPSCs results in rapid killing of the iPSCs (=<2 h) due to the significant accumulation of the peptide assemblies in the nuclei of iPSCs. The phosphopentapeptide is innocuous to normal cells (e.g., HEK293 and hematopoietic progenitor cell (HPC)) because normal cells hardly overexpress ALP. Inhibiting ALP, mutating the l-phosphotyrosine from the C-terminal to the middle of the phosphopentapeptides, or replacing l-leucine to d-leucine in the phosphopentapeptide abolishes the intranuclear assemblies of the pentapeptides. Treating the l-phosphopentapeptide with cell lysate of normal cells (e.g., HS-5) confirms the proteolysis of the l-pentapeptide. This work, as the first case of intranuclear assemblies of peptides, not only illustrates the application of enzymatic noncovalent synthesis for selectively targeting nuclei of cells but also may lead to a new way to eliminate other pathological cells that express a high level of certain enzymes.
Insights
A novel phosphopentapeptide selectively eliminates undifferentiated human induced pluripotent stem cells (iPSCs) by forming intranuclear assemblies. This targeted approach offers a promising strategy for safe iPSC clinical applications by avoiding normal cell toxicity.
Area of Science:
- Biochemistry
- Stem Cell Biology
- Nanotechnology
Background:
- Tumorigenic risk of undifferentiated human induced pluripotent stem cells (iPSCs) hinders clinical translation.
- Selective elimination of undifferentiated iPSCs is crucial for safe cell-based therapies.
Purpose of the Study:
- To develop a novel method for selectively eliminating undifferentiated iPSCs.
- To investigate the mechanism of peptide assembly formation and cell targeting.
Main Methods:
- Synthesis of an l-phosphopentapeptide with self-assembly properties.
- Enzymatic dephosphorylation by alkaline phosphatase (ALP) overexpressed in iPSCs.
- Characterization of peptide assembly morphology (micelles, nanofibers) using circular dichroism and FTIR.
- Assessment of iPSC viability and normal cell toxicity.
Main Results:
- The phosphopentapeptide forms intranuclear α-helical assemblies in iPSCs upon ALP-catalyzed dephosphorylation, leading to rapid cell death (<2 h).
- Normal cells lacking significant ALP expression are unaffected, demonstrating high selectivity.
- Assembly formation is dependent on ALP activity, phosphotyrosine position, and leucine chirality.
Conclusions:
- Enzymatic noncovalent synthesis enables selective targeting of cell nuclei via intranuclear peptide assemblies.
- This approach provides a novel strategy for eliminating undifferentiated iPSCs, addressing a key barrier to their clinical use.
- The findings may extend to targeting other pathological cells overexpressing specific enzymes.
Related Concept Videos
Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Induced Pluripotent Stem Cells
Methods of Nuclear Reprogramming

